Diligence memo · auto-generated · as of July 2, 2026
Merrimack Pharmaceuticals Inc
Merrimack Pharmaceuticals Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Merrimack Pharmaceuticals Inc operates in Pharmaceuticals, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Merrimack Pharmaceuticals Inc has raised $77M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $77M on 2011-04-06.
Most recent recorded round closed around 2011-04-06.
Valuation (modeled)modeled
Provath models Merrimack Pharmaceuticals Inc at approximately $2.7B (range $250M–$7.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.50× the median modeled value of Series C Pharmaceuticals companies in 2010–2012 (12 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 15.2 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 88% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 96% of those peers.
Closest niche peers: Acadia Pharmaceuticals Inc, Agios Pharmaceuticals Inc, PCAS Patient Care Automation Services Inc., China Medicine Corp, Brickell Bay Acquisition Corp..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.